NCT00564733View on ClinicalTrials.gov

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

March 31, 2012

Conditions
Malignant Pleural EffusionStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

carboplatin

Given IV

DRUG

docetaxel

Given IV

DRUG

gemcitabine hydrochloride

Given IV

DRUG

paclitaxel

Given IV

PROCEDURE

computed tomography

Undergo FDG PET/CT

PROCEDURE

positron emission tomography

Undergo FDG PET/CT

RADIATION

fludeoxyglucose F 18

Given IV

OTHER

imaging biomarker analysis

Correlative studies

Trial Locations (2)

98104

Harborview Medical Center, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00564733 - FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter